In the United States, bladder cancer is the sixth most common cancer. When cancer is confined to the tissue lining the inner surface of the bladder and has not invaded the bladder's muscle layer, it is classified as non-muscle-invasive bladder cancer (NMIBC). It represents about 80% of all bladder cancer cases and is associated with a high recurrence rate of approximately 50 to 80% over five years. Johnson & Johnson's INLEXZO and Urogen's ZUSDURI are some of the approved drugs for non-muscle-invasive bladder cancer.
The company we are profiling today is Relmada Therapeutics Inc. (RLMD), which is developing a drug for non-muscle invasive bladder cancer.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.